Topic Listing for Peregrine Pharmaceuticals

Account Account Debtor
Additional Costs Administration Plan
Advances Affiliate
Against Agent
Agreement Amendment Plan
Amendments Writing Integration Amortization Payment
Anti-angiogenesis Agents Anti-phospholipid Therapy
Anti-terrorism Laws Antibody
Antigen Antigen 8211
Applicable Laws Application Payments Proceeds
Assignee Lender Attachment
Authorization Financing Statements Avid
Avid Liens Base Libor Rate
Bavituximab Bavituximab Anti-cancer Program
Bavituximab Anti-viral Program Become Involved Lawsuits Protect Enforce Patents Expensive Time
Beneficial Owner Blocked Person
Bluecrest Bluecrest Capital Finance
Borrower Borrower8217s Books
Borrowers Integrated Group Borrowing Resolutions
Business Cancellation Regrant Options
Cannot License Sell Cotara Delayed Never Further Developed Cash Equivalents
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Cgmp
Change Control Changes Business Management Ownership Locations
Claims Code
Collateral Collateral Account
Commitments Commodity Account
Common Stock Communication
Compensation Committee Report Competition
Compliance Compliance Anti-terrorism Laws
Compliance Certificate Conditions Precedent Credit Extensions
Conditions Precedent Initial Credit Extension Confidentiality
Consent Independent Contingent Obligation
Contractual Obligations Control Agreement
Controls Procedures Corporate Governance
Corporation Cost Contract Manufacturing
Cost Vouchers Cotara
Cotara 8211 Counterparts
Covenant Default Covenant Deliver
Credit Extension Criminal Proceeding
Critical Accounting Policies Customer Concentration Geographic Area Financial Information
Cytokine Cytokine 8211
Dea Default
Default Rate Definitions
Demand Waiver Dependency Radiolabeling Supplier Negatively Impact Ability Complete Clinical
Deposit Account Designated Deposit Account
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Discount Rate Dispositions
Distributions Investments Documents Incorporated Reference
Dollar Limitation Drug Application
Due Organization Authorization Effect Termination Service
Effective Amount Effective Date Term Plan
Eligibility Employee
Employment Service Rights Encumbrance
Equipment Erisa
Event Default Evidence Insurance
Executive Compensation Exercisability
Exercise Date Exercise Price
Exercise Term Options Exhibits Report Form 8-k
Fair Market Value Fda
Fdca Fees
Final Invoices Vouchers -final Payment Final Payment
Financial Statements Exhibits Financial Statements Reports Certificates
Financial Statements Supplementary Data Financing
Financing Securities Purchase Agreement Financing Shelf Registration Statement Form S-3 Number 333-109982
Form 10-q Franklin Avenue Suite 100 Tustin California 92780 Address
Full Disclosure Funding Date
Further Assurances Gaap
General Intangibles Glioblastoma Multiforme
Governing Law Government Compliance
Government Regulation Governmental Approval
Governmental Approvals Governmental Authority
Grant Security Interest Group
Growth Capital Advances Growth Capital Draw Period
Growth Capital Line Had Significant Losses Anticipate Future
Highlights 2005 Https Wawfebmil
Human Resources Inal Invoice8221
Inal Voucher8221 Incentive Options
Ind Indebtedness
Indemnification Expenses Indemnified Taxes
Indemnitees Insider
Insolvency Insolvency Proceeding
Insurance Intellectual Property
Intellectual Property Rights Inter-company Debt Contribution
Interest Other Expense Interest Other Income
Interest Period Interest Rate Determination Date
Inventory Inventory Returns
Investment Invoices
Joint Liability Judgments
Landlord Waiver Laws
Legal Proceedings Lenders
Lenders8217 Expenses Liability Collateral
Libor Rate Lien
Lien Priority Limited Transferability Options
Liquidity Capital Resources Liquidity Common Stock Adversely Affected Delisted Nasdaq Smallcap
Litigation Litigation Cooperation
Loan Documents Lose Qualified Management Scientific Personnel Unable Attract Retain
Maintenance Collateral Accounts Manufacture Products Avids Customers Subject Government Regulation
Manufacturing Facilities Not Continue Meet Regulatory Requirements Limited Manufacturing Raw Materials
Marketing Potential Products Material Adverse Change
Material Deviation Financial Statements Material Intellectual Property
Maximum Lawful Rate Mergers Acquisitions
Method Exercise Midcap Funding Llc
Misrepresentations Monoclonal Antibody
Monoclonal Antibody 8211 New Potential Accounting Pronouncements Impact Future Financial Position
Non-statutory Option Not Able Compete Competitors Biotechnology Industry Because Them
Not Applicable Notices
Notices Defaults Events Default Number 0-17085
Obligations Ofac
Ofac Lists Oncology
Operating Accounts Operating Documents
Option Option Other Rights
Option Terms Optionee
Optionees Representations Other Agreements
Other Information Other Licenses
Other Nformation Outstanding Indebtedness Midcap Finacial Llc Bluecrest Capital Finance
Overview Parent
Part Participant
Party Possession Assets Patents Trade Secrets
Paul Lytle Pay Official
Payment Default Payment Interest Credit Extensions
Payments Taxes Peregrine Pharmaceuticals Announces Financial Results
Peregrine Pharmaceuticals Inc Peregrine Pharmaceuticals Inc Managements Report Internal Control Over
Peregrine Pharmaceuticals Inc Subsidiaries Registrant Permanent Disability Permanently Disabled
Permits Permitted Avid Transaction
Permitted Indebtedness Permitted Investments
Permitted Liens Person
Pharmacokinetic Pharmacokinetic 8211
Phospholipids Plan
Plan Administrator Plan Provisions Prevail
Power Attorney Pre-clinical
Pre-clinical 8211 Preferred Stock 5000000
Prepayment Fee Procedures Borrowing
Proceeds Product Development Efforts Not Successful
Products Promise Pay
Properties Protective Payments
Purchase Price Purpose Plan
Pursuant Securities Exchange Act 1934 Quantitative Qualitative Disclosures Market Isk
Quantitative Qualitative Disclosures Market Risk Register
Registered Organization Regulatory Approvals 409a Compliance Strategy
Regulatory Change Regulatory Compliance
Regulatory Developments Release
Report Independent Registered Public Accounting Firm Repurchase Rights
Required Permit Requirement Law
Research Development Reserve Percentage
Response Evaluation Criteria Solid Tumors 8220recist8221 Responsible Officer
Results Operations Financial Condition Reverse Stock Split
Right Set Off Rights Remedies
Risk Factors Risk Factors Forward-looking Statements
Sale Substantial Shares Common Stock Depress Price Sarbanes-oxley Act 2002
Securities Account Security Ownership Certain Beneficial Owners Management Related Stockholder
Security Stock Ownership Certain Beneficial Owners Management Selling General Administrative Expenses
Send Email Notifications Service
Severability Provisions Share Escrow Legends
Shareholder Shareholder Rights
Signature Signatures
Significant Product Liability Exposure Because Maintain Only Limited Solvency
Stated Rate Steven King
Stock Exchange Stock Issuance Agreement
Stock Issuances Stock Subject Plan
Strict Construction Structure Plan
Submission Matters Vote Security Holders Subordinated Debt
Subsidiaries Investments Subsidiary
Successors Assigns Survival
Table Contents Tax Returns Payments Pension Contributions
Taxes Taxes Pensions
Term Margin Component Termination Employment Death
Time Essence Total Revenues
Tranche Transactions Affiliates
Transfer Treasury Rate
Tumor Necrosis Therapy 8220tnt8221 Tumor Necrosis Therapy Cotara
Tustin Calif 2008 Unable Obtain Protect Enforce Patent Rights Effectively Exploit
United States Securities Exchange Utsw Agreement
Vascular Targeting Agents Vtas Vasopermeation Enhancement Agents
Vesting Vesting Provisions
Vta Licensing Collaborations Waiver Remedies Cumulative
Warrants Withdrawals Recalls Adverse Test Results Other Matters
Withholding Yield Maintenance Amount
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki